Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 24 Apr 20 424B4 Prospectus supplement with pricing info
- 24 Apr 20 EFFECT Notice of effectiveness
- 23 Apr 20 S-1/A IPO registration (amended)
-
20 Apr 20 S-1/A IPO registration (amended)
- 28 Feb 20 S-1 IPO registration
ORIC similar filings
Filing view
External links
Exhibit 23.1
When the transaction referred to under the heading “Reverse Stock Split” in note 11 of the notes to the financial statements has been consummated, we will be in a position to render the following consent.
/s/ KPMG LLP
Consent of Independent Registered Public Accounting Firm
The Board of Directors
ORIC Pharmaceuticals, Inc.:
We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.
San Diego, California
April , 2020